Today Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect.
David Colpman joins Forendo Pharma’s Board of Directors
AppointmentsForendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, today announces the appointment of David Colpman as a non-executive director to its Board of Directors.
Parexel Appoints Jamie Macdonald as CEO
AppointmentsCompany Co-founder Josef von Rickenbach to retire after 35 years of leadership; serve as Chairman of the Board.
Experts forecast the industry’s biggest developments at Pharmapack Europe
BackgroundPersonalised medicines, intelligent packaging and FDA deadlines seen as major trends for pharma packaging in 2018.
Heidelberg Pharma inks US$334m R&D contract with Magenta Therapeutics
Latest NewsUnder an exclusive licence option agreement, Heidelberg Pharma will develop ATACs (alpha-amanitin antibody conjugates) for Magenta Therapeutics Inc. across several targeted conditioning programmes for bone marrow transplants.
Brief Overview of The Trianni Mouse Platform
Sponsored PublicationsTRIANNI’s antibody discovery platform, The Trianni Mouse, represents best-in-class technology for efficient generation of fully-human monoclonal antibodies.
Investors keen to put money into AMR SMEs
Latest NewsInvestments into new drugs to tackle antimicrobial resistance (AMR) are set to boost the participation of SMEs. At the 11th Berlin Conference on Life Sciences, two new financing initiatives, which focus on innovations developed by SMEs, were presented to 200+ AMR stakeholders.
Santhera’s idebenone not efficient in PPMS patients
Latest NewsSwiss Santhera Pharmaceuticals EU-approved LHON treatment Raxone (idebenone) has failed to show clinical efficacy in another indication: After US and EU regulators rejected an extension of market approval in Duchenne muscular dystrophy last September, an NIH-sponsored trail now showed no difference to placebo treatment in patients with primary progressive multiple sclerosis (PPMS).
Radek píek to become new CEO of SOTIO
AppointmentsSOTIO, a biotechnology company belonging to the PPF Group, announces today the appointment of Professor Radek píek as Chief Executive Officer.
Inhaled IL-4 halts neuron destruction in MS models
Latest NewsAn US-German team has found a way to halt the inflammatory brain cell destruction in mice with multiple sclerosis (MS) without suppression of the human immune system.
Mission Therapeutics promotes Paul Thompson to VP
AppointmentsToday Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect.